Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic
US5599794A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 22, 1993 |
| Grant date | Feb 4, 1997 |
| Priority date | — |
| Expiry date | Apr 22, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61F2210/0047
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
RACT). P. Unge, et al. "Does Omeprazole improve antimicrobial therapy directed towards gastric Campylobacter-pylori in patients with antral gastritis" Scandinavian Journal of Gastroenterology 1989, 24 (Suppl. 167) p. 49-54 (ARTICLE). "Which regimen for H pylori eradication?" SCRIP No. 1861 Oct. 5, 1983, p. 23. S. Rune, "Helicobacter pylori, Peptic Ulcer Disease and Inhibition of Gastric Acid Secretion" Digestion 1992; 51 (Suppl. 1): 11-16. McDermott, et al., Science, The Absorption of Orally Administered Penicillin, Mar. 22, 1946, pp. 359-361. McNulty, et al., Eur. J. Clin. Microbiol. Infect. Dis., Susceptibility of Clinical Isolates, Aug., 1988, pp. 566-569. The Lancet, Clarithromycin and Omeprazole, vol. 340, Jul. 25, 1992. Goodwin, Worsley, Peptic Ulcer Disease, 1992, Current Science, 8:122-127. Loo, Sherman, Matlow; Helicobacter pylori Infection, Anti-microbial Agents & Chemotherapy, May, 1992, pp. 1133-1135. LREP FRM White & Case
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.